ストックスクリーナーアプリを入手
2.72
1.87%
0.05
前日終値:
$2.67
開ける：
$2.7112
24時間の取引高:
1.41M
Relative Volume:
0.97
時価総額：
$193.58M
収益：
$20.76M
当期純損益:
$-132.49M
株価収益率:
-1.0187
EPS:
-2.67
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
+4.62%
1か月 パフォーマンス:
+35.32%
6か月 パフォーマンス:
+11.93%
1年 パフォーマンス:
-53.34%
1日の値動き範囲:
$2.64
$2.85
1週間の範囲:
$2.45
$2.85
52週間の値動き範囲:
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.72 | 190.03M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
Is C4 Therapeutics Inc. forming a bottoming baseDollar Strength & AI Enhanced Execution Alerts - Newser
Can C4 Therapeutics Inc. recover in the next quarterEarnings Recap Summary & AI Driven Stock Movement Reports - Newser
Historical volatility pattern of C4 Therapeutics Inc. visualizedJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Machine Learning Models Forecast C4 Therapeutics Inc. UptickPortfolio Growth Summary & Daily Stock Momentum Reports - beatles.ru
Will C4 Therapeutics Inc. benefit from seasonalityWeekly Trading Summary & Daily Volume Surge Signals - خودرو بانک
What is C4 Therapeutics Inc.’s book value per shareEarnings Recap Report & Precise Trade Entry Recommendations - خودرو بانک
What is the dividend yield of C4 Therapeutics Inc.July 2025 Summary & Safe Entry Point Identification - خودرو بانک
Can C4 Therapeutics Inc. sustain its profitability2025 Trading Volume Trends & Verified Stock Trade Ideas - خودرو بانک
Can C4 Therapeutics Inc. weather a recessionQuarterly Risk Review & Weekly High Return Forecasts - خودرو بانک
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Biogen’s IND for BIIB-142 accepted by FDA - BioWorld MedTech
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33% - simplywall.st
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart overlay techniques for tracking C4 Therapeutics Inc.Trade Volume Report & Short-Term Trading Opportunity Alerts - Newser
Real time breakdown of C4 Therapeutics Inc. stock performanceQuarterly Market Review & Verified Technical Trade Signals - Newser
Visual trend scoring systems applied to C4 Therapeutics Inc.July 2025 Sector Moves & Growth Focused Entry Reports - Newser
How to integrate C4 Therapeutics Inc. into portfolio analysis toolsJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser
Does C4 Therapeutics Inc. show high probability of reboundJuly 2025 Levels & Accurate Intraday Trading Signals - Newser
Building trade automation scripts for C4 Therapeutics Inc.2025 Performance Recap & Comprehensive Market Scan Insights - Newser
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biogen Inc. shares fall 2.38% intraday as C4 Therapeutics highlights recent achievements in Biogen. - AInvest
C4 Therapeutics (CCCC) Receives Buy Rating from Guggenheim | CCC - GuruFocus
Why is C4 Therapeutics Inc. stock going downJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - خودرو بانک
C4 Therapeutics shares rise 1.95% premarket after Biogen's IND application for IRAK4 degrader accepted by FDA. - AInvest
Biogen's IND Application Accepted by FDA for C4 Therapeutics' Treatment of Autoimmune Diseases - AInvest
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential - Investing.com
What the charts say about C4 Therapeutics Inc. todayJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - Newser
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 - biospace.com
How hedge fund analytics apply to C4 Therapeutics Inc. stockStop Loss & Short-Term High Return Strategies - Newser
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics to Present Updated Data on Cemsidomide for Multiple Myeloma at IMS Annual Meeting 2025 - Quiver Quantitative
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting - The Manila Times
C4 Therapeutics to Present Data from the Phase 1 Trial of - GlobeNewswire
Novel Multiple Myeloma Drug Trial Results: C4 Therapeutics' Cemsidomide Shows Promise in Phase 1 Study - Stock Titan
How moving averages guide C4 Therapeutics Inc. trading2025 Winners & Losers & High Accuracy Investment Entry Signals - Newser
Is C4 Therapeutics Inc. on track to beat earningsJuly 2025 Sentiment & Fast Entry High Yield Tips - خودرو بانک
Detecting support and resistance levels for C4 Therapeutics Inc.2025 Analyst Calls & AI Enhanced Trade Execution Alerts - Newser
Best data tools to analyze C4 Therapeutics Inc. stockJuly 2025 Spike Watch & Weekly Market Pulse Alerts - Newser
Protara Therapeutics’ Equity Inducement Grants: A Strategic Catalyst for Talent Retention and Long-Term Value Creation - AInvest
Entrada Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Protara Therapeutics, Inc. reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
大文字化:
|
ボリューム (24 時間):